European Patent Board Rules in Favour of Puma Biotechnology - IP News Shots
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology - Crunchbase Company Profile & Funding
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ… https://t.co/sWLJCNJzQV"
Puma Biotechnology
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Conspiracy Theory: Did Puma Biotech Exec Resign Because of Bad News Ahead? | BioSpace
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters
PUMA BIOTECHNOLOGY: Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer | FDA Health News
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotechnology Inc
Where Will Puma Biotechnology Inc (PBYI) Stock Go Next After It Is Lower By 3.91% in a Week?
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | FiercePharma
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
PUMA BIOTECHNOLOGY: FDA Approves Labeling Supplement for Puma Biotechnology's NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer | FDA Health News
Puma Biotechnology
HCW starts Puma Biotechnology at buy; PT $15 | BioTuesdays
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology Crashed After Lagging More Bullish Views For Breast Cancer Drug Nerlynx | Stock News & Stock Market Analysis - IBD
